SOUTHBOROUGH, Mass. — Veristat said it has named industry veteran Kim McLean Boericke as its new Chief Executive Officer, succeeding Patrick Flanagan, who will transition to the company’s Board of Directors after 13 years in the role.
Boericke, who previously served as Veristat’s Chief Operating Officer, brings more than 25 years of leadership and operational experience in the clinical research industry. As CEO, she will focus on continuing Veristat’s evolution as a provider of advanced data analytics, scientific insight, and regulatory support for complex clinical development programs.
“I’m delighted to pass the baton to Kim at this exciting time for the company. She is a scientifically astute leader with high-quality standards and a record of success,” Flanagan said. “Veristat is unique in that it was built on a strong foundation of scientific integrity, a client focus, and high-quality clinical trial support. Kim’s expertise, combined with her strategic and efficient approach to implementing solutions, will advance Veristat as the company continues to innovate and grow in supporting our clients’ most complex clinical trials and the patients they serve.”
Before joining Veristat, Boericke held senior executive roles at Thread, ICON, IQVIA, i3 Research, and INC Research, where she was involved in advising, planning, and delivering clinical development programs. She has also served as Chairwoman and Independent Director for MAPI Trust.
“The clinical research industry is undergoing significant change as businesses look to innovate, implement new technologies, and bolster their deep scientific expertise, and Veristat is at the forefront of this transformation,” said CJ Burnes, Partner at WindRose Health Investors, Veristat’s majority investor. “We are thrilled to welcome Kim as the next CEO and believe she is the right leader to drive the business through its next stage of growth.”
“Veristat is at the forefront of clinical research, and I’m excited to continue building on our company’s vision to help bring the most advanced therapies to patients,” Boericke said. “My immediate focus will be on expanding Veristat’s early-stage strategic consulting capabilities, enabling closer collaboration with clients to finalize and deliver drug development programs, optimize clinical trial design, and streamline regulatory pathways to approval.”
Veristat said Boericke will also focus on expanding the company’s therapeutic specialization in oncology, neurology, and rare diseases, positioning the organization to better support global regulatory submissions and help clients advance innovative therapies for patients with unmet medical needs.
